Press Release
Stay updated with our latest news and media
Daewoong Launches SGLT-2 Inhibitor ‘Enavogliflozin’ in Indonesia, Expanding Treatment Options for 20 Million Patients with Diabetes
Writer
Manager
June 27, 2026
- Indonesia has the world’s fifth-largest adult diabetes population at 20.4 million; SGLT-2 inhibitor launched to expand treatment options
- Clinical evidence in Asian patients with type 2 diabetes shared, highlighting glucose-lowering efficacy, body weight, and metabolic indicators
- Korean and Indonesian medical professionals discuss expanded academic exchange to improve the diabetes treatment environment

Daewoong Pharmaceutical Indonesia (hereinafter “Daewoong”) announced the Indonesian launch of enavogliflozin, its self-developed SGLT-2 inhibitor for diabetes, and hosted a scientific symposium to commemorate the launch at the 14th Annual Scientific Meeting of the Indonesian Society of Endocrinology (PIT PERKENI 2026) in Bandung, Indonesia.

The congress took place from June 26 to 28 at Hotel Aryaduta Bandung, bringing together approximately 500 medical professionals from across Indonesia, including endocrinologists and internal medicine specialists. At the symposium, Daewoong shared research findings on SGLT-2 inhibitors in Asian patients with type 2 diabetes and discussed ways to improve the diabetes treatment environment.

Honored guests pose for a group photo at the Grand Launch of enavogliflozin, Daewoong Pharmaceutical Indonesia’s SGLT-2 inhibitor antidiabetic therapy. From left to right: 1) dr. Wicak Prasetiadi, Head of Brand & Marketing, Daewoong Pharmaceutical Indonesia; 2) Prof. Dr. dr. Em Yunir, Sp.PD, K-EMD, Chairman of PERKENI; 3) Prof. Dr. dr. Hikmat Permana, Sp.PD, K-EMD, Head of the Division of Endocrinology, Padjadjaran University / Dr. Hasan Sadikin General Hospital Bandung; 4) Seong-soo Park, CEO, Daewoong Pharmaceutical; 5) Prof. Son Jang Won, Director of the Korean Diabetes Association (KDA); 6) Prof. Yong-ho Lee, Professor of Endocrinology, Yonsei University College of Medicine, South Korea; and 7) Hyoung Cheol Park, Head of ETC Marketing Division, Daewoong Pharmaceutical.

According to the International Diabetes Federation (IDF) Diabetes Atlas 2024, Indonesia had approximately 20.4 million adults with diabetes, the fifth-largest number globally. The IDF projects this figure to rise to approximately 28.6 million by 2050 and reports that the number of undiagnosed patients is estimated at around 15 million. As diabetes can lead to serious complications such as cardiovascular and kidney diseases, treatment approaches need to consider not only glycemic control but also metabolic, cardiovascular, and renal risk.

At the symposium, Daewoong introduced clinical data and scientific evidence for its self-developed SGLT-2 inhibitor for diabetes. In particular, discussions focused on the characteristics of Asian patients with type 2 diabetes, who may have metabolic risks such as insulin resistance and abdominal obesity even with a relatively low body mass index (BMI), as well as related research findings.

All participants pose for a group photo during the launch of enavogliflozin at the 14th National Endocrinology Forum and Annual Scientific Meeting of the Indonesian Society of Endocrinology 2026 (PIT PERKENI 2026), held on June 27, 2026, in Bandung, West Java.

Prof. Dr. dr. Em Yunir, Sp.PD, K-EMD, President of PERKENI, stated, “This new drug launch is meaningful because it brings a new treatment option to patients.” He added, “Indonesia faces a growing diabetes burden, and collaboration among healthcare professionals, academic societies, and industry is important to improve treatment quality and long-term patient outcomes.”

In the subsequent scientific session, Prof. Yong-ho Lee from the Division of Endocrinology and Metabolism at Yonsei University Severance Hospital in Korea and Prof. Dr. dr. Hikmat Permana, Sp.PD, K-EMD from Hasan Sadikin Hospital in Indonesia participated as speakers, sharing the clinical evidence and applicability of the new therapy. The session was moderated by Prof. So-hun Kim from the Division of Endocrinology and Metabolism at Inha University Hospital in Korea and Prof. dr. Putu Moda Arsana, Sp.PD-KEMD, FINASIM, professor at the Faculty of Medicine, Brawijaya University in Indonesia.

Prof. Yong-ho Lee explained, “This new treatment is an SGLT-2 inhibitor supported by clinical evidence in Asian patients with type 2 diabetes.” He added, “When treating Asian patients, healthcare professionals need to consider not only glucose-lowering efficacy but also changes in metabolic indicators such as body weight and insulin resistance when selecting treatment.”

From left to right: 1) Prof. Yong-ho Lee, MD, PhD, Director, Committee of Clinical Research, Korean Diabetes Association; 2) Prof. So-hun Kim, MD, PhD, Director, Committee of International Liaison, Korean Diabetes Association; 3) Prof. Dr. dr. Hikmat Permana, Sp.PD, K-EMD, Head, Division of Endocrinology Padjadjaran University / RSUP Dr. Hasan Sadikin Bandung; 4) Prof. dr. Putu Moda Arsana, Sp.PD-KEMD, Senior Endocrinologist, RSUD Dr. Saiful Anwar, Malang, Indonesia, Faculty of Medicine, Brawijaya University, Malang during the panel discussion session of the Envlo Grand Launch Dinner Symposium.

The event also included a signing ceremony for a memorandum of understanding (MOU) between the Korean Diabetes Association (KDA) and the Indonesian Society of Endocrinology (PERKENI). The agreement was established to expand cooperation in joint research and medical education in the field of diabetes.

Prof. Sung-rae Kim, Chairman of the Korean Diabetes Association and Professor of Endocrinology at Bucheon St. Mary’s Hospital, The Catholic University of Korea, who led the MOU between the two societies, said, “This MOU serves as a bridge toward the shared goal of improving diabetes care through scientific research and education.” He added, “We will continue meaningful academic exchange through joint research and educational collaboration.”

Shawn Park, CEO of Daewoong Pharmaceutical, said, “We hope this launch will provide a new treatment option for patients with type 2 diabetes in Indonesia. Daewoong will expand cooperation with healthcare professionals in line with academic exchange between the two societies and contribute to improving the diabetes treatment environment in Indonesia.”

Shawn Park, Chief Executive Officer (CEO) of Daewoong Pharmaceutical, delivered opening remarks at the official launch of enavogliflozin, a treatment for diabetes, held on June 27 in Bandung, West Java.
recent post
Forward
Press Release
Daewoong Launches SGLT-2 Inhibitor ‘Enavogliflozin’ in Indonesia, Expanding Treatment Options for 20 Million Patients with Diabetes
Press Release
Daewoong Highlights Cholesterol Management for Patients with Diabetes at PIT PERKENI 2026; Only 5 in 100 Patients at High Cardiovascular Risk Achieve Target Levels